Critical illness trial, 2002
A trial in 33 men with prolonged critical illness reported that GHRP-2 with TRH and GnRH reactivated several hormone axes more than GHRP-2 used alone. Reported in the cited paper.
SourceLoading…
Research Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →
The directory
83 listed
BioPeptide Technologies
LA Peptides
Main Peptides
Peak Lab Peptides
Royal Peptides
Ventra Sciences
ZC LabsNewsletter · Quarterly
Get notified about new lab results, price drops and supplier coupons before everyone else.
We respect your privacy. No spam.
GHRP-2 is a synthetic hexapeptide growth hormone secretagogue acting on the ghrelin receptor. Under the name pralmorelin it is used clinically in Japan as a diagnostic agent for growth hormone deficiency, which is its best supported application.
Vendor listings
Show prices as
14 listings · GHRP-2
In stock5mgseen 3d ago
In stock5mgseen 3d ago
In stock5mgseen 4d ago
In stock5mgseen 7d ago
In stock5mgseen 4d ago
In stock10mgseen 4d ago
In stock10mgseen 4d ago
In stock5mgseen 5d ago
In stock10mgseen 3d ago
In stock15mgseen 4d ago
In stock10mgseen 5d ago
In stock10mgseen 3d ago
Out of stock5mgseen 4d ago
Out of stock10mgseen 5d ago
Overview
GHRP-2 is a synthetic hexapeptide growth hormone secretagogue acting on the ghrelin receptor. Under the name pralmorelin it is used clinically in Japan as a diagnostic agent for growth hormone deficiency, which is its best supported application.
What the research reports
Outcomes described across the published GHRP-2 literature and ongoing study. Read each as research context rather than a promised personal result.
Strong GH pulse production
Produces a stronger and more selective growth hormone pulse than GHRP-6, with less hunger and lower cortisol and prolactin elevation. Reported in research settings.
Diagnostic test reliability
Pralmorelin reliably separates growth hormone deficient patients from healthy controls using a peak cutoff of 15.0 micrograms per litre. Reported in research settings.
Alternative to insulin testing
A 2013 cohort found the GHRP-2 and arginine tests acceptable alternatives to the insulin tolerance test for diagnosing adult deficiency. Reported in research settings.
Defined saturation dose limit
Published work places the saturation dose near 100 mcg, roughly 1 mcg per kilogram, above which returns diminish sharply. Reported in research settings.
Synergy with GHRH analogue use
Combining with a GHRH analogue produces a larger pulse than either pathway on its own, which underpins most stacked protocols. Reported in research settings.
Dosage and protocol
Research protocols use 100 to 300 mcg subcutaneously two or three times daily. Doses above 300 mcg raise cortisol and prolactin. Figures describe study protocols, not a personal regimen.
Clinical evidence
The published GHRP-2 record, labeled by strength so you can see what is settled and what is still emerging.
A trial in 33 men with prolonged critical illness reported that GHRP-2 with TRH and GnRH reactivated several hormone axes more than GHRP-2 used alone. Reported in the cited paper.
SourceA 1998 phase 1 study in 10 children reported predictable and significant increases in growth hormone after GHRP-2 administration over a two hour window. Reported in the cited paper.
SourceA cohort of 71 Japanese patients found the arginine and GHRP-2 tests acceptable alternatives to the insulin tolerance test for adult deficiency diagnosis. Reported in the cited paper.
SourceInteractions
Questions